Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
The analysis of operating activity ratios reveals a high level of efficiency in asset management and a consistent approach to liability settlement over the five-year period ending December 31, 2023. A general trend toward increased working capital efficiency is evident, despite some volatility in receivables turnover.
- Receivables Management
- The receivables turnover ratio experienced a peak of 66.78 in 2020 before declining to 45.69 in 2021 and stabilizing around 51.75 by 2023. This volatility is mirrored in the average receivable collection period, which remained exceptionally short, fluctuating between 5 and 8 days. Such low collection periods suggest a highly efficient credit-to-cash conversion process or a revenue model characterized by rapid payment cycles.
- Payables Management
- Payables turnover remained relatively stable, ranging from 7.57 to 8.97. The average payables payment period showed a slight increase from 41 days in 2019 to a peak of 48 days in 2020, before settling at 42 days in 2023. This consistency indicates a disciplined and predictable strategy for managing short-term obligations to suppliers and vendors.
- Working Capital Utilization
- The working capital turnover ratio demonstrated a consistent upward trajectory from 7.19 in 2019 to a peak of 10.27 in 2022, followed by a slight moderation to 9.47 in 2023. This trend indicates an improvement in the company's ability to generate revenue relative to its investment in net working capital, reflecting enhanced operational productivity over the observed period.
Overall, the operational cycle is characterized by a significant gap between the rapid collection of receivables and the more extended payment of payables. This disparity suggests a favorable cash flow position, as the company recovers funds from customers significantly faster than it settles its own short-term liabilities.
AI Ask an analyst for more
Turnover Ratios
Average No. Days
Receivables Turnover
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| External revenues | 105,305) | 92,488) | 82,877) | 76,001) | 64,387) | |
| Receivables, net of allowances | 2,035) | 1,674) | 1,814) | 1,138) | 1,056) | |
| Short-term Activity Ratio | ||||||
| Receivables turnover1 | 51.75 | 55.25 | 45.69 | 66.78 | 60.97 | |
| Benchmarks | ||||||
| Receivables Turnover, Competitors2 | ||||||
| Abbott Laboratories | 6.11 | 7.02 | 6.64 | — | — | |
| Elevance Health Inc. | 18.08 | 18.81 | 20.66 | — | — | |
| Intuitive Surgical Inc. | 6.30 | 6.60 | 7.30 | — | — | |
| Medtronic PLC | 5.21 | 5.71 | 5.51 | — | — | |
| UnitedHealth Group Inc. | 17.27 | 18.22 | 20.07 | — | — | |
| Receivables Turnover, Sector | ||||||
| Health Care Equipment & Services | 13.74 | 14.33 | 14.76 | — | — | |
| Receivables Turnover, Industry | ||||||
| Health Care | 7.66 | 8.22 | 8.00 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Receivables turnover = External revenues ÷ Receivables, net of allowances
= 105,305 ÷ 2,035 = 51.75
2 Click competitor name to see calculations.
An analysis of operating activity reveals a consistent upward trajectory in external revenues alongside fluctuations in the efficiency of receivable collections between 2019 and 2023.
- External Revenue Growth
- Revenues exhibited uninterrupted annual growth over the five-year period, increasing from US$ 64,387 million in 2019 to US$ 105,305 million in 2023. This steady expansion indicates a significant increase in the scale of the company's top-line operations.
- Net Receivables Trends
- Receivables, net of allowances, showed a general upward trend, rising from US$ 1,056 million in 2019 to US$ 2,035 million in 2023. A notable increase occurred in 2021, where balances jumped to US$ 1,814 million, followed by a brief contraction in 2022 before reaching a period peak in 2023.
- Receivables Turnover Efficiency
- The receivables turnover ratio demonstrated volatility over the observed period. Efficiency improved from 60.97 in 2019 to a peak of 66.78 in 2020, followed by a sharp decline to 45.69 in 2021. Although the ratio recovered to 55.25 in 2022, it declined slightly to 51.75 by the end of 2023. The correlation between the decline in turnover and the increase in net receivables suggests periods of slower collection velocity relative to the rapid growth in total revenues.
AI Ask an analyst for more
Payables Turnover
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Benefits | 88,394) | 75,690) | 69,199) | 61,628) | 53,857) | |
| Benefits payable | 10,241) | 9,264) | 8,289) | 8,143) | 6,004) | |
| Short-term Activity Ratio | ||||||
| Payables turnover1 | 8.63 | 8.17 | 8.35 | 7.57 | 8.97 | |
| Benchmarks | ||||||
| Payables Turnover, Competitors2 | ||||||
| Abbott Laboratories | 4.19 | 4.15 | 4.21 | — | — | |
| Elevance Health Inc. | 7.72 | 7.47 | 7.59 | — | — | |
| Intuitive Surgical Inc. | 12.69 | 13.78 | 14.45 | — | — | |
| Medtronic PLC | 4.03 | 4.46 | 4.98 | — | — | |
| UnitedHealth Group Inc. | 7.47 | 7.26 | 7.63 | — | — | |
| Payables Turnover, Sector | ||||||
| Health Care Equipment & Services | 7.14 | 6.94 | 7.18 | — | — | |
| Payables Turnover, Industry | ||||||
| Health Care | 5.97 | 5.79 | 5.84 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Payables turnover = Benefits ÷ Benefits payable
= 88,394 ÷ 10,241 = 8.63
2 Click competitor name to see calculations.
Between 2019 and 2023, a consistent expansion in both benefits expenditures and benefits payable is evident, reflecting a scaling of operational obligations. While the absolute values of these items have grown significantly, the payables turnover ratio has remained within a narrow range, indicating a stabilized cycle of liability settlement.
- Benefits Expenditure Trend
- Benefits costs exhibited uninterrupted annual growth, rising from 53,857 million US dollars in 2019 to 88,394 million US dollars in 2023. This represents a sustained increase in the volume of claims and services processed over the five-year period.
- Benefits Payable Growth
- The benefits payable balance increased from 6,004 million US dollars in 2019 to 10,241 million US dollars in 2023. The growth in payables closely mirrored the increase in total benefits, suggesting that accrual patterns for obligations have remained proportional to overall expenditure.
- Payables Turnover Stability
- The turnover ratio fluctuated between a low of 7.57 in 2020 and a high of 8.97 in 2019. Following a decline in 2020, the ratio showed a general recovery, reaching 8.63 by 2023. This stability indicates that the frequency with which benefit obligations are settled has remained consistent, despite the substantial increase in the total dollar volume of these transactions.
AI Ask an analyst for more
Working Capital Turnover
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current assets | 29,986) | 26,183) | 24,893) | 23,641) | 19,888) | |
| Less: Current liabilities | 18,872) | 17,178) | 15,331) | 13,394) | 10,929) | |
| Working capital | 11,114) | 9,005) | 9,562) | 10,247) | 8,959) | |
| External revenues | 105,305) | 92,488) | 82,877) | 76,001) | 64,387) | |
| Short-term Activity Ratio | ||||||
| Working capital turnover1 | 9.47 | 10.27 | 8.67 | 7.42 | 7.19 | |
| Benchmarks | ||||||
| Working Capital Turnover, Competitors2 | ||||||
| Abbott Laboratories | 4.54 | 4.48 | 3.87 | — | — | |
| Elevance Health Inc. | 7.83 | 8.37 | 7.23 | — | — | |
| Intuitive Surgical Inc. | 1.14 | 1.29 | 1.22 | — | — | |
| Medtronic PLC | 2.47 | 2.97 | 2.15 | — | — | |
| UnitedHealth Group Inc. | — | — | — | — | — | |
| Working Capital Turnover, Sector | ||||||
| Health Care Equipment & Services | 23.27 | 25.59 | 16.28 | — | — | |
| Working Capital Turnover, Industry | ||||||
| Health Care | 10.99 | 11.30 | 8.57 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Working capital turnover = External revenues ÷ Working capital
= 105,305 ÷ 11,114 = 9.47
2 Click competitor name to see calculations.
Between 2019 and 2023, a consistent upward trajectory in external revenues was observed, paired with fluctuating levels of working capital. This dynamic resulted in a general improvement in the efficiency of working capital utilization through 2022, followed by a slight moderation in the final year of the analyzed period.
- Revenue Expansion
- External revenues demonstrated uninterrupted growth over the five-year period, rising from 64,387 million USD in 2019 to 105,305 million USD by 2023. This sustained increase indicates a significant expansion in the scale of operations.
- Working Capital Management
- Working capital exhibited a non-linear trend, increasing to 10,247 million USD in 2020 before experiencing a two-year decline to 9,005 million USD in 2022. A notable increase occurred in 2023, with working capital rising to 11,114 million USD, the highest level recorded in the period.
- Working Capital Turnover Dynamics
- The working capital turnover ratio improved steadily from 7.19 in 2019 to a peak of 10.27 in 2022, reflecting an increasing ability to generate revenue relative to the invested operating liquidity. The decrease to 9.47 in 2023 is a direct result of working capital growing at a faster rate than external revenues during that fiscal year.
AI Ask an analyst for more
Average Receivable Collection Period
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Receivables turnover | 51.75 | 55.25 | 45.69 | 66.78 | 60.97 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average receivable collection period1 | 7 | 7 | 8 | 5 | 6 | |
| Benchmarks (no. days) | ||||||
| Average Receivable Collection Period, Competitors2 | ||||||
| Abbott Laboratories | 60 | 52 | 55 | — | — | |
| Elevance Health Inc. | 20 | 19 | 18 | — | — | |
| Intuitive Surgical Inc. | 58 | 55 | 50 | — | — | |
| Medtronic PLC | 70 | 64 | 66 | — | — | |
| UnitedHealth Group Inc. | 21 | 20 | 18 | — | — | |
| Average Receivable Collection Period, Sector | ||||||
| Health Care Equipment & Services | 27 | 25 | 25 | — | — | |
| Average Receivable Collection Period, Industry | ||||||
| Health Care | 48 | 44 | 46 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 51.75 = 7
2 Click competitor name to see calculations.
The analysis of short-term operating activity ratios indicates a high level of efficiency in the management of accounts receivable. The company maintains an exceptionally brief collection cycle, suggesting an optimized credit-to-cash conversion process that minimizes liquidity risk associated with outstanding receivables.
- Receivables Turnover
- The turnover ratio exhibited volatility between 2019 and 2023. A peak was observed in 2020 at 66.78, followed by a significant contraction to 45.69 in 2021. This downward shift suggests a temporary slowing in the velocity of receivable collections relative to credit sales. However, a recovery occurred in 2022 with a ratio of 55.25, before settling at 51.75 in 2023.
- Average Receivable Collection Period
- The collection period remains consistently low, fluctuating between five and eight days. The period reached its most efficient point in 2020 at five days, which corresponded with the peak turnover ratio. The subsequent increase to eight days in 2021 aligns with the observed dip in turnover. In the most recent two fiscal years, the collection period has stabilized at seven days, demonstrating a consistent and rapid recovery of funds.
AI Ask an analyst for more
Average Payables Payment Period
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Payables turnover | 8.63 | 8.17 | 8.35 | 7.57 | 8.97 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average payables payment period1 | 42 | 45 | 44 | 48 | 41 | |
| Benchmarks (no. days) | ||||||
| Average Payables Payment Period, Competitors2 | ||||||
| Abbott Laboratories | 87 | 88 | 87 | — | — | |
| Elevance Health Inc. | 47 | 49 | 48 | — | — | |
| Intuitive Surgical Inc. | 29 | 26 | 25 | — | — | |
| Medtronic PLC | 91 | 82 | 73 | — | — | |
| UnitedHealth Group Inc. | 49 | 50 | 48 | — | — | |
| Average Payables Payment Period, Sector | ||||||
| Health Care Equipment & Services | 51 | 53 | 51 | — | — | |
| Average Payables Payment Period, Industry | ||||||
| Health Care | 61 | 63 | 63 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 8.63 = 42
2 Click competitor name to see calculations.
The analysis of short-term operating activity indicates a period of relative stability in the management of accounts payable between 2019 and 2023, characterized by a notable fluctuation in 2020 followed by a consistent return toward baseline levels.
- Payables Turnover
- The turnover ratio experienced a decline in 2020, dropping from 8.97 to 7.57. A recovery trend followed, with the ratio increasing to 8.35 in 2021, experiencing a slight dip to 8.17 in 2022, and rising to 8.63 by the end of 2023. This trajectory suggests a general increase in the efficiency and frequency of settling obligations with suppliers over the latter half of the period.
- Average Payables Payment Period
- The duration required to settle payables peaked in 2020 at 48 days, an increase from 41 days in 2019. This expansion suggests a temporary slowing of cash outflows toward creditors. Subsequently, the payment period trended downward, recording 44 days in 2021 and 45 days in 2022, before settling at 42 days in 2023. The proximity of the 2023 figure to the 2019 baseline indicates a restoration of previous payment cycles and liquidity management patterns.
AI Ask an analyst for more